2 References 17. Ashraf MW, Peltoniemi MA, Olkkola KT, Neuvonen PJ, Saari TI. Semimechanistic population pharmacokinetic model to predict the drugdrug interaction between S-ketamine and ticlopidine in healthy human volunteers. CPT Pharmacometrics Syst Pharmacol. 2018; 7: 687–697 doi: 10.1002/psp4.12346. 18. Perez-Ruixo C, Rossenu S, Zannikos P, Nandy P, Singh J, Drevets WC, al. et. Population pharmacokinetics of esketamine nasal spray and its metabolite norketamine in healthy subjects and patients with treatment resistant depression. Clin Pharmacokin. 2021; 60: 501–516 doi: 10.1007/s40262-020-00953-4. 19. Chong C, Schug SA, Page-Sharp M, Jenkins B, Ilett K. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain. Clin Drug Invest. 2009; 29: 317–324 doi: 10.2165/00044011-200929050-00004. 20. Kroin JS, Das V, Moric M, Buvanendran A. Efficacy of ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain. Reg Anesth Pain Med. 2019; 44: 111–117 doi: 10.1136/rapm-2018-000013. 21. Rolan P, Lim S, Sunderland V, Liu Y, Molnar V. The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol. 2013; 77: 1011–1016 doi: 10.1111/bcp.12264. 22. Peltoniemi MA, Saari TL, Hagelberg NM, Laine K, Kurkinen KJ, Neuvonen PJ, al. et. Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. Basic Clin Pharmacol Toxicol. 2021; 111: 325–332 doi: 10.1111/j.1742-7843.2012.00908.x. 23. Fanta S, Kinnunen M, Backman JT, Kalso E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015; 71: 441–447 doi: 10.1007/s00228-015-1826-y. 39
RkJQdWJsaXNoZXIy MTk4NDMw